New efforts to reveal the ties between doctors and drug firms
The earnings picture may be cloudy today in the drug business, but sun is shining in from another quarter. Today is the first day of data-gathering for the newly implemented Physician Payments Sunshine Act.
Over the last decade or so, the FDA has quietly become an agent of organized scientific fraud designed to promote the profits of drug companies at the expense of public health. One of the ways this is accomplished is by rigging drug review panels with industry “experts” who maintain financial ties to pharmaceutical companies.
Wiser prescription drug use could cut health costs by billions: study
Avoidable costs of more than $200 billion are incurred each year in the U.S. healthcare system as a result of medicines not being used responsibly by patients and healthcare professionals, according to a new study released today by the IMS Institute for Healthcare Informatics. This represents 8% of the United States’ total annual healthcare expenditures and amounts to millions of avoidable hospital admissions, outpatient treatments, pharmaceutical prescriptions and emergency room visits for patients.
The American medical system is corrupt, ineffective and unnecessarily costly
” The American medical system is corrupt, ineffective and unnecessarily costly. These outcomes are due to state violence on behalf of the politically connected elite (namely private insurers, physicians, pharmaceutical and medical device companies). Artificial scarcity, price-gouging, misallocation of research funding and the suppression of alternative (non-patentable) therapies can be ameliorated by revoking state-conferred elite privilege and re-establishing cooperative, mutualized healthcare financing. ”
Fears of a crisis in drug innovation have grown over the years
” Despite the more than $50 billion that U.S. pharmaceutical companies have spent every year since the mid-2000s to discover new medications, drugmakers have barely improved on old standbys developed decades ago. ”
” Selling pharmaceuticals is an extremely competitive business and companies know that they need to put their best face forward. That face is usually a smiling drug representative whose job it is to teach your physician about the newest medicines being produced today.
In Canada the drug industry spends roughly $3 billion per year marketing its products, two-thirds of which goes towards the salaries of the sales reps who visit our physicians regularly, and the drug samples they use to enhance their one-on-one learning sessions. “
” Here are six new Pharma marketing initiatives that are guaranteed to keep investor expectations high along with our insurance premiums. The secret? Recycling old and discredited drugs and marketing diseases to sell the few new ones. ‘
” There is good news and bad news about attention deficit/hyperactivity disorder (ADHD) — that is, if you’re a drug company. The bad news is the kid market has peaked out with 4.5 million U.S. children now carrying the label. The good news is adult ADHD is an emerging market. In fact, adult ADHD, with symptoms similar to pediatric ADHD such as impulsivity, distractibility and difficulty paying attention, following instructions and meeting deadlines, is the next big thing “.